Skip to content

Author

Ying-Ding Ruan

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Immune checkpoint inhibitor‑based vs. non‑immunotherapy subsequent treatment after progression on first‑line chemoimmunotherapy in extensive‑stage small cell lung cancer: A meta‑analysis

. First‑line chemoimmunotherapy is currently a standard treatment for extensive‑stage small cell lung cancer (ES‑SCLC), but the value of immune checkpoint inhibitor (ICI)‑based subsequent treatment after progression remains uncertain. The present meta‑analysis assessed the efficacy and safety of ICI‑based vs. non‑immun...

Chuan Long, Ying-Ding Ruan, Ai-Ming Yang et al. · 0 citations
Meta-analysis Open access Sep 2026

Clinical and molecular prognostic factors associated with outcomes of first-line osimertinib in EGFR-Mutated advanced NSCLC: a systematic review and meta-analysis

Osimertinib is the standard first-line therapy for epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC), but outcomes remain heterogeneous. This meta-analysis evaluated baseline clinical and molecular prognostic factors associated with poorer outcomes in this setting. PubMed, Emba...

Ying-Ding Ruan, Hong-Sheng Xue, Chuan Long et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.